Comerica Bank’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $3.72M | Sell |
62,650
-5,326
| -8% | -$290K | 0.01% | 768 |
|
|
2025
Q3 | $3.68M | Sell |
67,976
-9,841
| -13% | -$563K | 0.01% | 839 |
|
|
2025
Q2 | $4.28M | Sell |
77,817
-5,214
| -6% | -$307K | 0.02% | 748 |
|
|
2025
Q1 | $5.87M | Buy |
83,031
+21,520
| +35% | +$1.45M | 0.02% | 599 |
|
|
2024
Q4 | $4.04M | Sell |
61,511
-3,716
| -6% | -$249K | 0.02% | 785 |
|
|
2024
Q3 | $4.58M | Sell |
65,227
-7,991
| -11% | -$668K | 0.02% | 733 |
|
|
2024
Q2 | $6.03M | Buy |
73,218
+66,161
| +938% | +$5.51M | 0.03% | 590 |
|
|
2024
Q1 | $616K | Sell |
7,057
-296
| -4% | -$26.5K | ﹤0.01% | 1786 |
|
|
2023
Q4 | $709K | Buy |
7,353
+2,037
| +38% | +$180K | ﹤0.01% | 1705 |
|
|
2023
Q3 | $470K | Sell |
5,316
-29,334
| -85% | -$2.61M | ﹤0.01% | 1822 |
|
|
2023
Q2 | $63 | Buy |
+34,650
| New | +$3.26M | 0.01% | 156 |
|
|
2022
Q4 | $349K | Buy |
3,122
+305
| +11% | +$28.6K | ﹤0.01% | 1900 |
|
|
2022
Q3 | $253K | Buy |
2,817
+371
| +15% | +$33K | ﹤0.01% | 2001 |
|
|
2022
Q2 | $211K | Sell |
2,446
-3,261
| -57% | -$260K | ﹤0.01% | 2078 |
|
|
2022
Q1 | $460K | Sell |
5,707
-5,225
| -48% | -$437K | ﹤0.01% | 1900 |
|
|
2021
Q4 | $928K | Sell |
10,932
-8,998
| -45% | -$742K | 0.01% | 1607 |
|
|
2021
Q3 | $1.47M | Sell |
19,930
-4,646
| -19% | -$367K | 0.01% | 1495 |
|
|
2021
Q2 | $1.84M | Sell |
24,576
-1,833
| -7% | -$145K | 0.01% | 1359 |
|
|
2021
Q1 | $2.08M | Sell |
26,409
-588
| -2% | -$48K | 0.01% | 1330 |
|
|
2020
Q4 | $2.38M | Buy |
26,997
+2,838
| +12% | +$225K | 0.02% | 1197 |
|
|
2020
Q3 | $1.87M | Sell |
24,159
-192
| -0.8% | -$19.4K | 0.01% | 1169 |
|
|
2020
Q2 | $3.11M | Sell |
24,351
-15
| -0.1% | -$1.49K | 0.02% | 786 |
|
|
2020
Q1 | $2.37M | Buy |
24,366
+10,146
| +71% | +$874K | 0.02% | 821 |
|
|
2019
Q4 | $1.21M | Buy |
14,220
+694
| +5% | +$52.4K | 0.01% | 1434 |
|
|
2019
Q3 | $939K | Buy |
13,526
+55
| +0.4% | +$4.24K | 0.01% | 1566 |
|
|
2019
Q2 | $1.11M | Buy |
13,471
+797
| +6% | +$68.2K | 0.01% | 1468 |
|
|
2019
Q1 | $1.17M | Buy |
12,674
+2,614
| +26% | +$242K | 0.01% | 1479 |
|
|
2018
Q4 | $948K | Sell |
10,060
-36
| -0.4% | -$3.42K | 0.01% | 1574 |
|
|
2018
Q3 | $1.01M | Buy |
10,096
+565
| +6% | +$56.4K | 0.01% | 1586 |
|
|
2018
Q2 | $991K | Buy |
9,531
+2,489
| +35% | +$218K | 0.01% | 1653 |
|
|
2018
Q1 | $589K | Sell |
7,042
-142
| -2% | -$12.2K | ﹤0.01% | 1854 |
|
|
2017
Q4 | $656K | Sell |
7,184
-137
| -2% | -$11.9K | ﹤0.01% | 1820 |
|
|
2017
Q3 | $600K | Sell |
7,321
-37
| -0.5% | -$3.27K | ﹤0.01% | 1835 |
|
|
2017
Q2 | $662K | Buy |
7,358
+76
| +1% | +$6.91K | 0.01% | 1747 |
|
|
2017
Q1 | $701K | Buy |
7,282
+183
| +3% | +$16.3K | 0.01% | 1753 |
|
|
2016
Q4 | $617K | Buy |
+7,099
| New | +$610K | ﹤0.01% | 1784 |
|
|
2015
Q3 | – | Sell |
-3,062
| Closed | -$418K | – | 2051 |
|
|
2015
Q2 | $418K | Buy |
+3,062
| New | +$379K | ﹤0.01% | 1972 |
|
|
2014
Q2 | – | Sell |
-13,699
| Closed | -$934K | – | 2123 |
|
|
2014
Q1 | $934K | Buy |
13,699
+9
| +0.1% | +$663 | 0.01% | 1595 |
|
|
2013
Q4 | $963K | Sell |
13,690
-10,903
| -44% | -$740K | 0.01% | 1580 |
|
|
2013
Q3 | $1.78M | Sell |
24,593
-3,567
| -13% | -$237K | 0.01% | 1222 |
|
|
2013
Q2 | $1.57M | Buy |
+28,160
| New | +$1.75M | 0.01% | 1105 |
|
Other funds holding BMRN
Comerica Bank's BMRN Position: Q4 2025 in Review
Comerica Bank reduced its BioMarin Pharmaceuticals (BMRN) stake by 7.8% in Q4 2025, selling an estimated $290K and leaving 62,650 shares worth $3.72M. The position accounts for 0.01% of the portfolio, ranked #768.
Comerica Bank first reported a position in BMRN in Q2 2013 and has held it in 41 quarters since. The position peaked at $6.03M in Q2 2024. 539 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.
- Comerica Bank held 62,650 shares of BioMarin Pharmaceuticals worth $3.72M as of Q4 2025.
- Comerica Bank sold 5,326 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $290K.
- BioMarin Pharmaceuticals made up 0.01% of Comerica Bank's portfolio in Q4 2025, its #768 holding.
- Comerica Bank first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 41 quarters since.
- Comerica Bank's BioMarin Pharmaceuticals position peaked at $6.03M in Q2 2024.
- 539 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.
Based on Comerica Bank's 13F filing for Q4 2025, filed 29 Jan 2026.